Citations (121)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Songchen Zhao, Xintong Hu, Peiwen Zhou, Ang Li, Liguo Chen, Duo Wang, Jiaxue He & Yanfang Jiang. (2023) Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma. Cancer Biology & Therapy 24:1.
Read now
Read now
S. Elizabeth Franks, Kellsye P. Fabian, Ginette Santiago-Sánchez, Benjamin Wolfson & James W. Hodge. (2022) Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models. OncoImmunology 11:1.
Read now
Read now
Hue Tu Quach, Zhaohua Hou, Rebecca Y. Bellis, Jasmeen K. Saini, Alfredo Amador-Molina, Prasad S. Adusumilli & Yuquan Xiong. (2022) Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1. Expert Opinion on Investigational Drugs 31:11, pages 1187-1202.
Read now
Read now
Yohei Ozawa, Kristin C. Hicks, Christine M. Minnar, Karin M. Knudson, Jeffrey Schlom & Sofia R. Gameiro. (2021) Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. OncoImmunology 10:1.
Read now
Read now
Jacquelot N, Tellier J, Nutt Sl & Belz Gt. (2021) Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. OncoImmunology 10:1.
Read now
Read now
Christopher Larson, Bryan Oronsky, Corey A. Carter, Arnold Oronsky, Susan J. Knox, David Sher & Tony R. Reid. (2020) TGF-beta: a master immune regulator. Expert Opinion on Therapeutic Targets 24:5, pages 427-438.
Read now
Read now
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Xianguang Bai, Ming Yi, Ying Jiao, Qian Chu & Kongming Wu. (2019) Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. OncoTargets and Therapy 12, pages 9527-9538.
Read now
Read now
Julie M. Collins, Jason M. Redman & James L. Gulley. (2018) Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Review of Vaccines 17:8, pages 697-705.
Read now
Read now
Karin M. Knudson, Kristin C. Hicks, Xiaoling Luo, Jin-Qiu Chen, Jeffrey Schlom & Sofia R. Gameiro. (2018) M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. OncoImmunology 7:5.
Read now
Read now
Articles from other publishers (111)
Byoung Chul Cho, Jong Seok Lee, Yi-Long Wu, Irfan Cicin, Manuel Cobo Dols, Myung-Ju Ahn, Kristof Cuppens, Rémi Veillon, Ernest Nadal, Josiane Mourão Dias, Claudio Martin, Martin Reck, Edward B. Garon, Enriqueta Felip, Luis Paz-Ares, Francoise Mornex, Everett E. Vokes, Alex A. Adjei, Clifford Robinson, Masashi Sato, Yulia Vugmeyster, Andreas Machl, Francois Audhuy, Surendra Chaudhary & Fabrice Barlesi. (2023) Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. Journal of Thoracic Oncology 18:12, pages 1731-1742.
Crossref
Crossref
Rosemary J. Akhurst. (2023) From shape-shifting embryonic cells to oncology: The fascinating history of epithelial mesenchymal transition. Seminars in Cancer Biology 96, pages 100-114.
Crossref
Crossref
Zhuo Chen, Meng-Wei Yao, Xiang Ao, Qing-Jia Gong, Yi Yang, Jin-Xia Liu, Qi-Zhou Lian, Xiang Xu & Ling-Jing Zuo. (2023) The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells. Chinese Journal of Traumatology.
Crossref
Crossref
Sumeet Singh, Vinita Gouri & Mukesh Samant. (2023) TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer. Medical Oncology 40:11.
Crossref
Crossref
Nick A. Kuburich, Thiru Sabapathy, Breanna R. Demestichas, Joanna Joyce Maddela, Petra den Hollander & Sendurai A. Mani. (2023) Proactive and reactive roles of TGF-β in cancer. Seminars in Cancer Biology 95, pages 120-139.
Crossref
Crossref
Jingtao Zhang, Shuai Liu, Xiubao Chen, Xiangdong Xu & Fei Xu. (2023) Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy. Biomedicine & Pharmacotherapy 166, pages 115336.
Crossref
Crossref
Ghazaleh Khalili-Tanha, Hamid Fiuji, Masoumeh Gharib, Meysam Moghbeli, Nima Khalili-Tanha, Farzad Rahmani, Neda Shakour, Mina Maftooh, Seyed Mahdi Hassanian, Fereshteh Asgharzadeh, Soodabeh Shahidsales, Kazem Anvari, M.R. Mozafari, Gordon A. Ferns, Jyotsna Batra, Elisa Giovannetti, Majid Khazaei & Amir Avan. (2023) Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma. Life Sciences 328, pages 121865.
Crossref
Crossref
Zana Karami, Keywan Mortezaee & Jamal Majidpoor. (2023) Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated. International Immunopharmacology 122, pages 110648.
Crossref
Crossref
Zaroon, Numan yousaf, Shakira Aslam, Shahnila Qureshi & Hamid Bashir. (2023) In silico investigation of a novel anti-EGFR scFv-IL-24 fusion protein induces apoptosis in malignant cells. Journal of Molecular Modeling 29:9.
Crossref
Crossref
Fan Ye, Zihao Cai, Boyu Wang, Chenxi Zeng, Yu Xi, Shaojie Hu, Rirong Qu, Zhiwei Yuan, Jiaqi Yue, Yitao Tian, Xue Wang, Xiangning Fu & Lequn Li. (2023) TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT–Smad3–SHP1 Axis in Lung Adenocarcinoma. Cancer Research 83:13, pages 2262-2277.
Crossref
Crossref
Fangfang Liu, Qiong Wu, Zigang Dong & Kangdong Liu. (2023) Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacology & Therapeutics 247, pages 108458.
Crossref
Crossref
Max Kam-Kwan Chan, Emily Lok-Yiu Chan, Zoey Zeyuan Ji, Alex Siu-Wing Chan, Chunjie Li, Kam-Tong Leung, Ka-Fai To & Patrick Ming-Kuen Tang. (2023) Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy. Exploration of Targeted Anti-tumor Therapy, pages 316-343.
Crossref
Crossref
Valeria Ramundo, Maria Luisa Palazzo & Elisabetta Aldieri. (2023) TGF-β as Predictive Marker and Pharmacological Target in Lung Cancer Approach. Cancers 15:8, pages 2295.
Crossref
Crossref
Yu-Jie Zhou, Guoli Li, Jiyin Wang, Mengyuan Liu, Zihan Wang, Yu Song, Xulong Zhang & Xi Wang. (2023) PD-L1: expression regulation. Blood Science 5:2, pages 77-91.
Crossref
Crossref
Tianyin Ma, Zhang Chen, Yibo Chai, Xiangdong Gongye, Peng Xia, Chenming Qu, Ming Tian & Yufeng Yuan. (2023) Research progress on immunotherapy targeting the tumor immune microenvironment for cholangiocarcinoma*. Oncology and Translational Medicine 9:2, pages 49-55.
Crossref
Crossref
Fabrice Barlesi, Nicolas Isambert, Enriqueta Felip, Byoung Chul Cho, Dae Ho Lee, Julio Peguero, Guy Jerusalem, Nicolas Penel, Esma Saada-Bouzid, Pilar Garrido, Christoph Helwig, George Locke, Laureen S Ojalvo & James L Gulley. (2023) Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. The Oncologist 28:3, pages 258-267.
Crossref
Crossref
Jing Zhang, Zhimin Hu, Calista A. Horta & Jing Yang. (2023) Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. Seminars in Cancer Biology 88, pages 46-66.
Crossref
Crossref
Ibrahim Ozcan, Senem Akkoc, Hakan Alici, Seval Capanlar, Onur Sahin & Hakan Tahtaci. (2022) Novel Thioether‐Bridged 2,6‐Disubstituted and 2,5,6‐Trisubstituted Imidazothiadiazole Analogues: Synthesis, Antiproliferative Activity, ADME, and Molecular Docking Studies. Chemistry & Biodiversity 20:1.
Crossref
Crossref
Fen Wang, Mingyi Yang, Weichi Luo & Qing Zhou. (2022) Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer. Journal of the National Cancer Center 2:4, pages 243-262.
Crossref
Crossref
Anastasia E. Metropulos, Hidayatullah G. Munshi & Daniel R. Principe. (2022) The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial. eBioMedicine 86, pages 104380.
Crossref
Crossref
Valeria Lucarini, Ombretta Melaiu, Silvia D’Amico, Fabio Pastorino, Patrizia Tempora, Marco Scarsella, Marco Pezzullo, Adele De Ninno, Valentina D’Oria, Michele Cilli, Laura Emionite, Paola Infante, Lucia Di Marcotullio, Maria Antonietta De Ioris, Giovanni Barillari, Rita Alaggio, Luca Businaro, Mirco Ponzoni, Franco Locatelli & Doriana Fruci. (2022) Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Crossref
Jiao Deng, Wei Jiang, Liang Liu, Wenli Zhan, Yudi Wu & Xiangshang Xu. (2022) Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review). Oncology Letters 25:1.
Crossref
Crossref
Hyun Ju Yoon, Gi-Cheon Kim, Sejin Oh, Hakhyun Kim, Yong Keon Kim, Yunji Lee, Min Seo Kim, Gino Kwon, Yeon-Su Ok, Ho-Keun Kwon & Hyun Seok Kim. (2022) WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function. Experimental & Molecular Medicine 54:11, pages 1913-1926.
Crossref
Crossref
Gerhard A. Burger, Daphne N. Nesenberend, Carlijn M. Lems, Sander C. Hille & Joost B. Beltman. (2022)
Bidirectional crosstalk between epithelial–mesenchymal plasticity and IFN
γ
-induced PD-L1 expression promotes tumour progression
. Royal Society Open Science 9:11.
Crossref
Crossref
Fan Ye, Pingan Wu, Yaqiong Zhu, Guan Huang, Ying Tao, Zhencheng Liao & Yafeng Guan. (2022) Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma. Frontiers in Genetics 13.
Crossref
Crossref
Zhen-Hua Wu, Na Li, Zhang-Zhao Gao, Gang Chen, Lei Nie, Ya-Qiong Zhou, Mei-Zhu Jiang, Yao Chen, Juan Chen, Xiao-Fen Mei, Feng Hu & Hai-Bin Wang. (2022) Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy. Cancers 14:19, pages 4964.
Crossref
Crossref
Zerui Gao, Xingyi Ling, Chengyu Shi, Ying Wang & Aifu Lin. (2022) Tumor immune checkpoints and their associated inhibitors肿瘤免疫检查点及与其相关抑制剂. Journal of Zhejiang University-SCIENCE B 23:10, pages 823-843.
Crossref
Crossref
Paulien Kaptein & Daniela S. Thommen. (2022) Keeping track of the T cells that matter. Nature Cancer 3:9, pages 1015-1017.
Crossref
Crossref
Thomas Denize, Yue Hou, Jean-Christophe Pignon, Emily Walton, Destiny J. West, Gordon J. Freeman, David A. Braun, Catherine J. Wu, Saurabh Gupta, Robert J. Motzer, Michael B. Atkins, David McDermott, Toni K. Choueiri, Sachet A. Shukla & Sabina Signoretti. (2022) Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 28:18, pages 4045-4055.
Crossref
Crossref
Ginette S. Santiago-Sánchez, James W. Hodge & Kellsye P. Fabian. (2022) Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Frontiers in Immunology 13.
Crossref
Crossref
Tsung-Wei Chen, Wei-Ze Hung, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, Ji-An Liang, Chih-Yang Huang, Pei-Chen Yang, Kevin Chih-Yang Huang & K.S. Clifford Chao. (2022) Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. Cancer Letters 543, pages 215795.
Crossref
Crossref
Sofia R Gameiro, Julius Strauss, James L Gulley & Jeffrey Schlom. (2022) Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status. Experimental Biology and Medicine 247:13, pages 1124-1134.
Crossref
Crossref
François Lucia, Margaux Geier, Ulrike Schick & Vincent Bourbonne. (2022) Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy. Biomedicines 10:6, pages 1414.
Crossref
Crossref
James L. Gulley, Jeffrey Schlom, Mary Helen Barcellos‐Hoff, Xiao‐Jing Wang, Joan Seoane, Francois Audhuy, Yan Lan, Isabelle Dussault & Aristidis Moustakas. (2022) Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment. Molecular Oncology 16:11, pages 2117-2134.
Crossref
Crossref
Dengdi Hu, Zhaoqing Li, Bin Zheng, Xixi Lin, Yuehong Pan, Peirong Gong, Wenying Zhuo, Yujie Hu, Cong Chen, Lini Chen, Jichun Zhou & Linbo Wang. (2022) Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities. Cancer Communications 42:5, pages 401-434.
Crossref
Crossref
Lucas A. Horn, Paul L. Chariou, Sofia R. Gameiro, Haiyan Qin, Masafumi Iida, Kristen Fousek, Thomas J. Meyer, Margaret Cam, Dallas Flies, Solomon Langermann, Jeffrey Schlom & Claudia Palena. (2022) Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication. Journal of Clinical Investigation 132:8.
Crossref
Crossref
Szu-Ying ChenOns MamaiRosemary J. Akhurst. (2022) TGFβ: Signaling Blockade for Cancer Immunotherapy. Annual Review of Cancer Biology 6:1, pages 123-146.
Crossref
Crossref
Ruyue Xu, Xinkuang Liu, Amin Li, Li Song, Jiaojiao Liang, Jiafeng Gao & Xiaolong Tang. (2022) c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. Journal of Molecular Medicine 100:4, pages 585-598.
Crossref
Crossref
Jia Z. Shen, Zhixin Qiu, Qiulian Wu, Guoxin Zhang, Rebecca Harris, Dahui Sun, Juha Rantala, William D. Barshop, Linjie Zhao, Deguan Lv, Kwang-Ai Won, James Wohlschlegel, Olle Sangfelt, Heike Laman, Jeremy N. Rich & Charles Spruck. (2022) A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. Molecular Cell 82:6, pages 1123-1139.e8.
Crossref
Crossref
Nicholas P. Tschernia & James L. Gulley. (2022) Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy. BioDrugs 36:2, pages 153-180.
Crossref
Crossref
Qing Xia, Jing Jia, Chupeng Hu, Jinying Lu, Jiajin Li, Haiyan Xu, Jianchen Fang, Dongju Feng, Liwei Wang & Yun Chen. (2021) Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene 41:6, pages 865-877.
Crossref
Crossref
Chunxiao Xu, Bo Marelli, Jin Qi, Guozhong Qin, Huakui Yu, Hong Wang, Molly H. Jenkins, Kin-Ming Lo & Yan Lan. (2022) NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models. Translational Oncology 16, pages 101322.
Crossref
Crossref
Maoduo Zhang, Ying Yi Zhang, Yongze Chen, Jia Wang, Qiang Wang & Hezhe Lu. (2021) TGF-β Signaling and Resistance to Cancer Therapy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Farideh Ghalamfarsa, Seyyed Hossein Khatami, Omid Vakili, Mortaza Taheri-Anganeh, Amir Tajbakhsh, Amir Savardashtaki, Yousef Fazli, Leila Rezaei Uonaki, Zahra Shabaninejad, Ahmad Movahedpour & Ghasem Ghalamfarsa. (2021) Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. Immunotherapy 13:16, pages 1355-1367.
Crossref
Crossref
Christina H. Stuelten & Ying E. Zhang. (2021) Transforming Growth Factor-β: An Agent of Change in the Tumor Microenvironment. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Dandan Li, Nicholas Schaub, Theresa M. Guerin, Tashinga E. Bapiro, Frances M. Richards, Vicky Chen, Keyur Talsania, Parimal Kumar, Debra J. Gilbert, Jerome J. Schlomer, Seong-Jin Kim, Rebecca Sorber, Yaroslav Teper, Wendy Bautista, Claudia Palena, Chan-Young Ock, Duncan I. Jodrell, Nathan Pate, Monika Mehta, Yongmei Zhao, Serguei Kozlov & Udo Rudloff. (2021) T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer. Molecular Cancer Therapeutics 20:10, pages 1926-1940.
Crossref
Crossref
Nikolaos Charalampakis, Georgios Papageorgiou, Sergios Tsakatikas, Rodanthi Fioretzaki, Christo Kole, Stylianos Kykalos, Maria Tolia & Dimitrios Schizas. (2021) Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 13:13, pages 1113-1134.
Crossref
Crossref
Mana Taki, Kaoru Abiko, Masayo Ukita, Ryusuke Murakami, Koji Yamanoi, Ken Yamaguchi, Junzo Hamanishi, Tsukasa Baba, Noriomi Matsumura & Masaki Mandai. (2021) Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition. Clinical Cancer Research 27:17, pages 4669-4679.
Crossref
Crossref
Hay-Ran Jang, Sol-Bi Shin, Chang-Hyeon Kim, Jae-Yeon Won, Rong Xu, Da-Eun Kim & Hyungshin Yim. (2021) PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma. Cell Death & Differentiation 28:9, pages 2745-2764.
Crossref
Crossref
Giulia Lucibello, Baharia Mograbi, Gerard Milano, Paul Hofman & Patrick Brest. (2021) PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends in Molecular Medicine 27:9, pages 868-881.
Crossref
Crossref
Jihyun Moon, Yoo Min Oh & Sang-Jun Ha. (2021) Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications. BMB Reports 54:8, pages 403-412.
Crossref
Crossref
Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing H. Wang & Xiao-Jing Wang. (2021) Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Communications Biology 4:1.
Crossref
Crossref
Danielle M. Pastor & Jeffrey Schlom. (2021) Immunology of Lynch Syndrome. Current Oncology Reports 23:8.
Crossref
Crossref
Min Wang, Xiaoyang Zhai, Ji Li, Jingyuan Guan, Shuhui Xu, YuYing Li & Hui Zhu. (2021) The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Frontiers in Immunology 12.
Crossref
Crossref
Xuecong Wang & Jean Paul Thiery. (2021) Harnessing Carcinoma Cell Plasticity Mediated by TGF-β Signaling. Cancers 13:14, pages 3397.
Crossref
Crossref
Chia-Chi Lin, Toshihiko Doi, Kei Muro, Ming-Mo Hou, Taito Esaki, Hiroki Hara, Hyun Cheol Chung, Christoph Helwig, Isabelle Dussault, Motonobu Osada & Shunsuke Kondo. (2021) Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia. Targeted Oncology 16:4, pages 447-459.
Crossref
Crossref
Benjamin Tan, Adnan Khattak, Enriqueta Felip, Karen Kelly, Patricia Rich, Ding Wang, Christoph Helwig, Isabelle Dussault, Laureen S. Ojalvo & Nicolas Isambert. (2021) Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Targeted Oncology 16:4, pages 435-446.
Crossref
Crossref
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu & Quan Cheng. (2021) Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Nils Ludwig, Łukasz Wieteska, Cynthia S. Hinck, Saigopalakrishna S. Yerneni, Juliana H. Azambuja, Richard J. Bauer, Torsten E. Reichert, Andrew P. Hinck & Theresa L. Whiteside. (2021) Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti–PD-L1 Immunotherapy. Molecular Cancer Therapeutics 20:6, pages 1102-1111.
Crossref
Crossref
Benjamin Wolfson & James W. Hodge. (2021)
Next Generation Therapeutic Strateg‐Es:
Evolving
cancer immunotherapy through agents that
Engage
,
Expand
and
Enable
the anti‐tumor immune response
. ImmunoMedicine 1:1.
Crossref
Crossref
Mobina Jalalvand, Farzaneh Darbeheshti & Nima Rezaei. (2021) Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer. Immunotherapy 13:7, pages 587-603.
Crossref
Crossref
Li‐Na Pan, Yun‐Fang Ma, Zhen Li, Jia‐An Hu & Zhi‐Hong Xu. (2021) KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer. Cell Biology International 45:4, pages 795-803.
Crossref
Crossref
Margaret E. Gatti-Mays, Sofia R. Gameiro, Yohei Ozawa, Karin M. Knudson, Kristin C. Hicks, Claudia Palena, Lisa M. Cordes, Seth M. Steinberg, Deneise Francis, Fatima Karzai, Stanley Lipkowitz, Renee N. Donahue, Caroline Jochems, Jeffrey Schlom & James L. Gulley. (2021) Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Mu-Yang Huang, Xiao-Ming Jiang, Bing-Lin Wang, Yang Sun & Jin-Jian Lu. (2021) Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacology & Therapeutics 219, pages 107694.
Crossref
Crossref
Lucas A. Horn, Kristen Fousek, Duane H. Hamilton, James W. Hodge, John A. Zebala, Dean Y. Maeda, Jeffrey Schlom & Claudia Palena. (2021) Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. Cancers 13:5, pages 968.
Crossref
Crossref
Sergio Ayala-Mar, Javier Donoso-Quezada & José González-Valdez. (2021) Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy. Journal of Immunology Research 2021, pages 1-18.
Crossref
Crossref
Sebastian Marwitz, Carmen Ballesteros-Merino, Shawn M Jensen, Martin Reck, Christian Kugler, Sven Perner, Daniel Drömann, Torsten Goldmann & Bernard A Fox. (2021) Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer. Journal for ImmunoTherapy of Cancer 9:2, pages e001469.
Crossref
Crossref
Ming Yi, Mengke Niu, Linping Xu, Suxia Luo & Kongming Wu. (2021) Regulation of PD-L1 expression in the tumor microenvironment. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu & Jiang Chen. (2021) Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Therapeutic Advances in Medical Oncology 13, pages 175883592110180.
Crossref
Crossref
Mustafa Khasraw, Michael Weller, David Lorente, Kathryn Kolibaba, Chee Khoon Lee, Craig Gedye, Macarena I. de La Fuente, David Vicente, David A Reardon, Hui K Gan, Andrew M Scott, Isabelle Dussault, Christoph Helwig, Laureen S Ojalvo, Carole Gourmelon & Morris Groves. (2021) Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances 3:1.
Crossref
Crossref
Rik Derynck, Shannon J. Turley & Rosemary J. Akhurst. (2020) TGFβ biology in cancer progression and immunotherapy. Nature Reviews Clinical Oncology 18:1, pages 9-34.
Crossref
Crossref
Ho-Jae Lee. (2020) Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy. Journal of Cancer Prevention 25:4, pages 213-222.
Crossref
Crossref
Marina Chulkina, Ellen J. Beswick & Irina V. Pinchuk. (2020) Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation. International Journal of Molecular Sciences 21:23, pages 9165.
Crossref
Crossref
Maria Davern & Joanne Lysaght. (2020) Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers. Cancer Letters 495, pages 89-99.
Crossref
Crossref
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni & Francesco Gelsomino. (2020) The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. Cancers 12:11, pages 3129.
Crossref
Crossref
Toshihiko Doi, Yutaka Fujiwara, Takafumi Koyama, Masafumi Ikeda, Christoph Helwig, Morihiro Watanabe, Yulia Vugmeyster & Masatoshi Kudo. (2020) Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort. The Oncologist 25:9, pages e1292-e1302.
Crossref
Crossref
Hui Yi Chew, Riccardo Dolcetti & Fiona Simpson. (2020) Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors. British Journal of Clinical Pharmacology 86:9, pages 1711-1725.
Crossref
Crossref
Colby R. Maldini, Andrea C. Love, Kevin W. Tosh, Leo Li-Ying Chan, Kevin Gayout, Tim Smith & James L. Riley. (2020) Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry. Journal of Immunological Methods 484-485, pages 112830.
Crossref
Crossref
Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolas Isambert, Edward McClay, Ahmad Awada, Christian Borel, Laureen S Ojalvo, Christoph Helwig, P Alexander Rolfe, James L Gulley & Nicolas Penel. (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Journal for ImmunoTherapy of Cancer 8:2, pages e000664.
Crossref
Crossref
Luis Paz-Ares, Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Ki Hyeong Lee, Chia-Chi Lin, Maria Jose Flor, Massimo Di Nicola, Rosa Maria Alvarez, Isabelle Dussault, Christoph Helwig, Laureen S. Ojalvo, James L. Gulley & Byoung Chul Cho. (2020) Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. Journal of Thoracic Oncology 15:7, pages 1210-1222.
Crossref
Crossref
Alexander A. Strait & Xiao‐Jing Wang. (2020) The role of transforming growth factor‐beta in immune suppression and chronic inflammation of squamous cell carcinomas. Molecular Carcinogenesis 59:7, pages 745-753.
Crossref
Crossref
Claire Smalley Rumfield, Samuel T Pellom, Y Maurice Morillon II, Jeffrey Schlom & Caroline Jochems. (2020) Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. Journal for ImmunoTherapy of Cancer 8:1, pages e000612.
Crossref
Crossref
Lucas A. Horn, Kristen Fousek & Claudia Palena. (2020) Tumor Plasticity and Resistance to Immunotherapy. Trends in Cancer 6:5, pages 432-441.
Crossref
Crossref
Y. Maurice MorillonIIII, Claire Smalley Rumfield, Samuel T. Pellom, Ariana Sabzevari, Nicholas T. Roller, Lucas A. Horn, Caroline Jochems, Claudia Palena, John W. Greiner & Jeffrey Schlom. (2020) The Use of a Humanized NSG-β2m−/− Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa. Frontiers in Oncology 10.
Crossref
Crossref
Zhu Lingling, Liu Jiewei, Wang Li, Yan Danli, Zhou Jie, Li Wen, Pu Dan, Peng Lei & Zhou Qinghua. (2020) Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathology - Research and Practice 216:4, pages 152852.
Crossref
Crossref
Geng Wang, Risheng Tai, Yanshuang Wu, Shanru Yang, Jingjing Wang, Xiaolan Yu, Lei Lei, Zhiyan Shan & Na Li. (2020) The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. Cytokine & Growth Factor Reviews 52, pages 1-14.
Crossref
Crossref
Lucas A Horn, Jeffrey Riskin, Heidi A Hempel, Kristen Fousek, Hanne Lind, Duane H Hamilton, Kristen K McCampbell, Dean Y Maeda, John A Zebala, Zhen Su, Jeffrey Schlom & Claudia Palena. (2020) Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. Journal for ImmunoTherapy of Cancer 8:1, pages e000326.
Crossref
Crossref
Ritu Shrestha, Kim Bridle, Darrell Crawford & Aparna Jayachandran. (2020) TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Molecular Medicine Reports.
Crossref
Crossref
Xing-Ning Lai, Jun Li, Li-Bo Tang, Wen-Tong Chen, Lei Zhang & Li-Xia Xiong. (2020) MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer. International Journal of Molecular Sciences 21:4, pages 1193.
Crossref
Crossref
Hanne Lind, Sofia R Gameiro, Caroline Jochems, Renee N. Donahue, Julius Strauss, James L GulleyMD,MD,, Claudia Palena & Jeffrey Schlom. (2020) Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. Journal for ImmunoTherapy of Cancer 8:1, pages e000433.
Crossref
Crossref
Sebastian Marwitz, Kati Turkowski, Dörte Nitschkowski, Andreas Weigert, Julius Brandenburg, Norbert Reiling, Michael Thomas, Martin Reck, Daniel Drömann, Werner Seeger, Klaus F. Rabe, Rajkumar Savai & Torsten Goldmann. (2020) The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Frontiers in Oncology 9.
Crossref
Crossref
Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel-Ángel Berciano-Guerrero, Emilio Alba, Manuel Cobo, Volker Lauschke & Isabel Barragán. (2020) Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. Journal of Clinical Medicine 9:1, pages 286.
Crossref
Crossref
Alessandra Metelli, Bill X. WuBrian RiesenbergSilvia Guglietta, John D. HuckCatherine Mills, Anqi LiSaleh Rachidi, Carsten Krieg, Mark P. Rubinstein, Daniel T. GewirthShaoli SunMichael B. LillyAmy H. WahlquistDavid P. Carbone, Yiping YangBei Liu & Zihai Li. (2020) Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β. Science Translational Medicine 12:525.
Crossref
Crossref
Cinzia Fionda, Helena Stabile, Cristina Cerboni, Alessandra Soriani, Angela Gismondi, Marco Cippitelli & Angela Santoni. (2020) Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer. Journal of Clinical Medicine 9:1, pages 143.
Crossref
Crossref
Yuanyuan Jiang & Hanxiang Zhan. (2020) Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Letters 468, pages 72-81.
Crossref
Crossref
Leo Li-Ying Chan. 2020. Immuno-Oncology. Immuno-Oncology
13
34
.
Minyu Wang, Sen Wang, Jayesh Desai, Joseph A Trapani & Paul J Neeson. (2020) Therapeutic strategies to remodel immunologically cold tumors. Clinical & Translational Immunology 9:12.
Crossref
Crossref
Mark Owyong, Jonathan Chou, Renske JE van den Bijgaart, Niwen Kong, Gizem Efe, Carrie Maynard, Dalit Talmi-Frank, Inna Solomonov, Charlotte Koopman, Elin Hadler-Olsen, Mark Headley, Charlene Lin, Chih-Yang Wang, Irit Sagi, Zena Werb & Vicki Plaks. (2019) MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Science Alliance 2:6, pages e201800226.
Crossref
Crossref
Jian Chen, Julian A. Gingold & Xiaoping Su. (2019) Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends in Molecular Medicine 25:11, pages 1010-1023.
Crossref
Crossref
Justin J. Wilkins, Yulia Vugmeyster, Isabelle Dussault, Pascal Girard & Akash Khandelwal. (2019) Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types. Advances in Therapy 36:9, pages 2414-2433.
Crossref
Crossref
Benjamin E. Onderdonk & Steven J. Chmura. (2019) The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond. Frontiers in Oncology 9.
Crossref
Crossref
Breelyn A. Wilky. (2019) Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunological Reviews 290:1, pages 6-23.
Crossref
Crossref
Leo Li-Ying Chan, Kai W. Wucherpfennig & Lucas Ferrari de Andrade. (2019) Visualization and quantification of NK cell-mediated cytotoxicity over extended time periods by image cytometry. Journal of Immunological Methods 469, pages 47-51.
Crossref
Crossref
Jake S. O’Donnell, Michele W. L. Teng & Mark J. Smyth. (2018) Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology 16:3, pages 151-167.
Crossref
Crossref
Sara Musetti & Leaf Huang. (2018) Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy. ACS Nano 12:12, pages 11740-11755.
Crossref
Crossref
Jason M. Redman, Seth M. Steinberg & James L. Gulley. (2018) Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Naoki Takasaka, Robert I. Seed, Anthony Cormier, Andrew J. Bondesson, Jianlong Lou, Ahmed Elattma, Saburo Ito, Haruhiko Yanagisawa, Mitsuo Hashimoto, Royce Ma, Michelle D. Levine, Jean Publicover, Rashaun Potts, Jillian M. Jespersen, Melody G. Campbell, Fraser Conrad, James D. Marks, Yifan Cheng, Jody L. Baron & Stephen L. Nishimura. (2018) Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. JCI Insight 3:20.
Crossref
Crossref
Julius Strauss, Christopher R. Heery, Jeffrey Schlom, Ravi A. Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L. Marté, Renee N. Donahue, Italia Grenga, Lisa Cordes, Olaf Christensen, Lisa Mahnke, Christoph Helwig & James L. Gulley. (2018) Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clinical Cancer Research 24:6, pages 1287-1295.
Crossref
Crossref
Italia Grenga, Renee N. Donahue, Morgan L. Gargulak, Lauren M. Lepone, Mario Roselli, Marijo Bilusic & Jeffrey Schlom. (2018) Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urologic Oncology: Seminars and Original Investigations 36:3, pages 93.e1-93.e11.
Crossref
Crossref
Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. HernándezMolly H. JenkinsRachel E. FontanaAmit DeshpandeGeorge Locke, Helen SabzevariLaszlo RadvanyiKin-Ming Lo. (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Science Translational Medicine 10:424.
Crossref
Crossref
Caroline Jochems, Sarah R. Tritsch, Samuel Troy Pellom, Zhen Su, Patrick Soon-Shiong, Hing C. Wong, James L. Gulley & Jeffrey Schlom. (2017) Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824). Oncotarget 8:43, pages 75217-75231.
Crossref
Crossref